Clinical value of 18F-FDG-PET/CT in suspected serious disease with special emphasis on occult cancer.
Kamilla Bredlund CaspersenNikoletta GiannoutsouOke GerkeAbass AlaviPoul Flemming Høilund-CarlsenSoren HessPublished in: Annals of nuclear medicine (2018)
Cancer prevalence is substantial among patients with SSD. 18F-FDG-PET/CT is a promising option in this setting, in particular because a high negative predictive value equals a low incidence of cancer during follow-up. Further studies are needed to establish the role of 18F-FDG-PET/CT in SSD.